Avalyn Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	May '26 May 20, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Market Capitalization	1,172	-	-
Enterprise Value	1,035	-	-
Debt / Equity Ratio	0.01	0.01	-
Net Debt / Equity Ratio	-1.02	-1.02	-1.02
Net Debt / EBITDA Ratio	1.50	1.50	2.12
Net Debt / FCF Ratio	1.67	1.67	2.44
Quick Ratio	9.86	9.86	12.72
Current Ratio	10.19	10.19	13.08
Return on Equity (ROE)	-68.34%	-68.34%	-
Return on Assets (ROA)	-41.74%	-41.74%	-
Return on Capital Employed (ROCE)	-67.70%	-67.70%	-48.10%
Buyback Yield / Dilution	-	-259.46%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q